// App-Quantinova.ai

71 : Effective Targeting Of The P53/MDM2 Axis In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Richard B. Lock

Principal Investigators

  • Jennifer Richmond

  • Laura High

  • Hernan Carol

  • Kathryn Evans

  • Agnes M. Mendomo

  • Raushan T. Kurmasheva

  • Peter J. Houghton

  • Malcolm A. Smith

Medical Centers

  • Nationwide Children's Hospital, Columbus, OH

  • Children's Cancer Institute, University of New South Wales, Sydney, Australia.

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

  • Children's Cancer Institute Australia for Medical Research, University of New South Wales, Randwick, Australia

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of differentiation 45

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • RG-7112

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved